CoChat

Dihydroartemisinin counteracts fibrotic portal hypertension via farnesoid X receptor‐dependent inhibition of hepatic stellate cell contraction

Open access
Xu, Wenxuan, Lu, Chunfeng, Zhang, Feng, Shao, Jiangjuan, Yao, Shunyu, Zheng, Shizhong · 2017 · The FEBS Journal
Cited by 36

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

Portal hypertension is a frequent pathological symptom occurring especially in hepatic fibrosis and cirrhosis. Current paradigms indicate that inhibition of hepatic stellate cell (HSC) activation and contraction is anticipated to be an attractive therapeutic strategy, because activated HSC dominantly facilitates an increase in intrahepatic vein pressure through secreting extracellular matrix and contracting. Our previous in vitro study indicated that dihydroartemisinin (DHA) inhibited contractility of cultured HSC by activating intracellular farnesoid X receptor (FXR). However, the effect of DHA on fibrosis‐related portal hypertension still requires clarification. In this study, gain‐ and loss‐of‐function models of FXR in HSC were established to investigate the mechanisms underlying DHA protection against chronic CCl 4‐caused hepatic fibrosis and portal hypertension. Immunofluorescence staining visually showed a decrease in FXR expression in CCl 4‐administrated rat HSC but an increase in that in DHA‐treated rat HSC. Serum diagnostics and morphological analyses consistently indicated that DHA exhibited hepatoprotective effects on CCl 4‐induced liver injury. DHA also reduced CCl 4‐caused inflammatory mediator expression and inflammatory cell infiltration. These improvements were further enhanced by INT‐747 but weakened by Z‐guggulsterone. Noteworthily, DHA, analogous to INT‐747, significantly lowered portal vein pressure and suppressed fibrogenesis. Experiments on mice using FXR shRNA lentivirus consolidated the results above. Mechanistically, inhibition of HSC activation and contraction was found as a cellular basis for DHA to relieve portal hypertension. These findings demonstrated that DHA attenuated portal hypertension in fibrotic rodents possibly by targeting HSC contraction via a FXR activation‐dependent mechanism. FXR could be a target molecule for reducing portal hypertension during hepatic fibrosis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/febs.13956

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 36

Metadata

Authors
Xu, W., Lu, C., Zhang, F., Shao, J., Yao, S., & Zheng, S.
Venue
The FEBS Journal
Publisher
Wiley
Published
2016-11-29
Volume
284
Issue
1
Pages
114-133
ISSN
  • 1742-464X (ISSN-L)
  • 1742-4658
OpenAlex
W2551948525
Cited by
36
References
10
FWCI
2.23
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Dihydroartemisinin counteracts fibrotic portal hypertension via farnesoid X receptor‐dependent inhibition of hepatic stellate cell contraction. https://app.cochat.ai/papers/10.1111/febs.13956
The paper
Xu, W., Lu, C., Zhang, F., Shao, J., Yao, S., & Zheng, S. (2017). Dihydroartemisinin counteracts fibrotic portal hypertension via farnesoid X receptor‐dependent inhibition of hepatic stellate cell contraction. The FEBS Journal. https://doi.org/10.1111/febs.13956

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.